The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of immune checkpoint inhibitor (CPI) and EGFR tyrosine kinase inhibitor (TKI) sequence on time to treatment failure (TTF) among EGFR plus NSCLC treated in a community-based cancer research network.
 
Carissa Jones
Employment - HCA/Sarah Cannon
 
Rebecca Lachs
Employment - Sarah Cannon Research Institute
Stock and Other Ownership Interests - HCA Healthcare
Travel, Accommodations, Expenses - Sarah Cannon Research Institute
 
Emma Sturgill
Employment - HCA/Sarah Cannon
Stock and Other Ownership Interests - HCA Healthcare
 
Amanda Misch
No Relationships to Disclose
 
Caressa Lietman
No Relationships to Disclose
 
Suzanne Fields Jones
Employment - HCA/Sarah Cannon
Stock and Other Ownership Interests - HCA Healthcare
Consulting or Advisory Role - Amgen (Inst)
 
Melissa Lynne Johnson
Consulting or Advisory Role - Abbvie (Inst); Achilles Therapeutics (Inst); Amgen (Inst); Association of Community Cancer Centers (ACCC) (Inst); Astellas Pharma (I); AstraZeneca (Inst); Atreca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Checkpoint Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Incyte (Inst); Janssen Oncology (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Otsuka (I); Pfizer (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); WindMIL (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Apexigen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Artios (Inst); AstraZeneca (Inst); Atreca (Inst); BeiGene (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Checkpoint Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Hengrui Pharmaceutical (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kadmon (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neovia Oncology (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); PMV Pharma (Inst); Regeneron (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Stem CentRx (Inst); Syndax (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TCR2 Therapeutics (Inst); Tmunity Therapeutics, Inc. (Inst); University of Michigan (Inst); WindMIL (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
David R. Spigel
Leadership - ASCO (Inst)
Consulting or Advisory Role - Amgen (Inst); Aptitude Health (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Curio Science (Inst); Dracen (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Iksuda Therapeutics (Inst); Illumina (Inst); Intellisphere (Inst); Ipsen (Inst); Jazz Pharmaceuticals (Inst); Merck (Inst); Mirati Therapeutics (Inst); Molecular Templates (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); PharmaMar (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Sanofi/Aventis (Inst); Seagen (Inst); Takeda (Inst); TRIPTYCH Health Partners (Inst); TRM Oncology (Inst)
Research Funding - Aeglea Biotherapeutics (Inst); Agios (Inst); Apollomics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BIND Therapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Elevation Oncology (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); ImClone Systems (Inst); Immunogen (Inst); Ipsen (Inst); Janssen Oncology (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Molecular Partners (Inst); Nektar (Inst); Neon Therapeutics (Inst); Novartis (Inst); Novocure (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech; Novartis
 
Andrew Jacob McKenzie
No Relationships to Disclose